tambaku Xarelto was first introduced in 2011 as part of a new class of medications that have been aggressively promoted as superior to Warfarin (Coumadin), because it is easier to use and requires less frequent monitoring.

Unlike Warfarin, which can quickly be reversed when a hemorrhage or bleed develops, there is no approved reversal agent for Xarelto and the drug makers failed to properly highlight this fact.

It now appears that Bayer and Johnson & Johnson, the manufacturers of Xarelto, placed their desire for profits before consumer safety by withholding information about the risks of Xarelto likely fearing that doctors may be less inclined to switch to the newer anticoagulant if they may be left helpless and unable to stop bleeding that may develop.

In April 2011, a study of more than 8,000 people compared Xarelto to Lovenox in patients hospitalized for acute medical conditions, such as heart failure, infectious disease, and breathing difficulty.

Patients taking Xarelto had significantly higher rates of bleeding — they were more than twice as likely to experience bleeding compared to Lovenox. 4.1% of patients taking Xarelto experienced bleeding, compared to 1.7% taking Lovenox.

If you or a loved one used Xarelto and experienced:

  • Internal Bleeding
  • Gastrointestinal Bleeding
  • Kidney Bleeding
  • Stroke
  • Brain Hemorrhaging

You may be entitled to significant compensation from the manufacturer.

There are time deadlines to file a claim so don’t wait — act now.

Fields marked with a * are required.


Connect immediately with a National Information Systems attorney